Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.

Janas MM, Zlatev I, Liu J, Jiang Y, Barros SA, Sutherland JE, Davis WP, Liu J, Brown CR, Liu X, Schlegel MK, Blair L, Zhang X, Das B, Tran C, Aluri K, Li J, Agarwal S, Indrakanti R, Charisse K, Nair J, Matsuda S, Rajeev KG, Zimmermann T, Sepp-Lorenzino L, Xu Y, Akinc A, Fitzgerald K, Vaishnaw AK, Smith PF, Manoharan M, Jadhav V, Wu JT, Maier MA.

Nucleic Acids Res. 2019 Apr 23;47(7):3306-3320. doi: 10.1093/nar/gkz140.

2.

An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.

Liu J, Qin J, Borodovsky A, Racie T, Castoreno A, Schlegel M, Maier MA, Zimmerman T, Fitzgerald K, Butler J, Akinc A.

RNA. 2019 Feb;25(2):255-263. doi: 10.1261/rna.068916.118. Epub 2018 Nov 21.

PMID:
30463937
3.

Reversal of siRNA-mediated gene silencing in vivo.

Zlatev I, Castoreno A, Brown CR, Qin J, Waldron S, Schlegel MK, Degaonkar R, Shulga-Morskaya S, Xu H, Gupta S, Matsuda S, Akinc A, Rajeev KG, Manoharan M, Maier MA, Jadhav V.

Nat Biotechnol. 2018 Jul;36(6):509-511. doi: 10.1038/nbt.4136. Epub 2018 May 14.

PMID:
29786096
4.

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.

Nair JK, Attarwala H, Sehgal A, Wang Q, Aluri K, Zhang X, Gao M, Liu J, Indrakanti R, Schofield S, Kretschmer P, Brown CR, Gupta S, Willoughby JLS, Boshar JA, Jadhav V, Charisse K, Zimmermann T, Fitzgerald K, Manoharan M, Rajeev KG, Akinc A, Hutabarat R, Maier MA.

Nucleic Acids Res. 2017 Nov 2;45(19):10969-10977. doi: 10.1093/nar/gkx818.

5.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.

Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I, Kazmi R, Chowdary P, Gercheva-Kyuchukova L, Mamonov V, Timofeeva M, Soh CH, Garg P, Vaishnaw A, Akinc A, Sørensen B, Ragni MV.

N Engl J Med. 2017 Aug 31;377(9):819-828. doi: 10.1056/NEJMoa1616569. Epub 2017 Jul 10.

6.

5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.

Parmar R, Willoughby JL, Liu J, Foster DJ, Brigham B, Theile CS, Charisse K, Akinc A, Guidry E, Pei Y, Strapps W, Cancilla M, Stanton MG, Rajeev KG, Sepp-Lorenzino L, Manoharan M, Meyers R, Maier MA, Jadhav V.

Chembiochem. 2016 Jun 2;17(11):985-9. doi: 10.1002/cbic.201600130. Epub 2016 Apr 28.

PMID:
27121751
7.

RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver.

Yin H, Bogorad RL, Barnes C, Walsh S, Zhuang I, Nonaka H, Ruda V, Kuchimanchi S, Nechev L, Akinc A, Xue W, Zerial M, Langer R, Anderson DG, Koteliansky V.

J Hepatol. 2016 Apr;64(4):899-907. doi: 10.1016/j.jhep.2015.11.028. Epub 2015 Nov 30.

8.

Identification of siRNA delivery enhancers by a chemical library screen.

Gilleron J, Paramasivam P, Zeigerer A, Querbes W, Marsico G, Andree C, Seifert S, Amaya P, Stöter M, Koteliansky V, Waldmann H, Fitzgerald K, Kalaidzidis Y, Akinc A, Maier MA, Manoharan M, Bickle M, Zerial M.

Nucleic Acids Res. 2015 Sep 18;43(16):7984-8001. doi: 10.1093/nar/gkv762. Epub 2015 Jul 28.

9.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, Foster D, Milstein S, Charisse K, Kuchimanchi S, Maier MA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A.

Nat Med. 2015 May;21(5):492-7. doi: 10.1038/nm.3847. Epub 2015 Apr 13.

PMID:
25849132
10.

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.

Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, Taneja N, O'Shea J, Shaikh S, Zhang L, van der Sluis RJ, Jung ME, Akinc A, Hutabarat R, Kuchimanchi S, Fitzgerald K, Zimmermann T, van Berkel TJ, Maier MA, Rajeev KG, Manoharan M.

J Am Chem Soc. 2014 Dec 10;136(49):16958-61. doi: 10.1021/ja505986a. Epub 2014 Dec 1.

11.

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy.

Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, Nair JK, Akinc A, Barros SA, Kasperkovitz PV.

Mol Ther Nucleic Acids. 2014 Nov 18;3:e210. doi: 10.1038/mtna.2014.61.

12.

Development of LC-MS methods for quantitation of hepcidin and demonstration of siRNA-mediated hepcidin suppression in serum.

Li S, Nakayama T, Akinc A, Wu SL, Karger BL.

J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:110-9. doi: 10.1016/j.vascn.2014.09.008. Epub 2014 Oct 2.

PMID:
25281793
13.

The roles of individual mammalian argonautes in RNA interference in vivo.

Ruda VM, Chandwani R, Sehgal A, Bogorad RL, Akinc A, Charisse K, Tarakhovsky A, Novobrantseva TI, Koteliansky V.

PLoS One. 2014 Jul 3;9(7):e101749. doi: 10.1371/journal.pone.0101749. eCollection 2014.

14.

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight.

Dahlman JE, Barnes C, Khan O, Thiriot A, Jhunjunwala S, Shaw TE, Xing Y, Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL, Yin H, Racie T, Dong Y, Jiang S, Seedorf D, Dave A, Sandu KS, Webber MJ, Novobrantseva T, Ruda VM, Lytton-Jean AKR, Levins CG, Kalish B, Mudge DK, Perez M, Abezgauz L, Dutta P, Smith L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M, Danino D, Tuder RM, von Andrian UH, Akinc A, Schroeder A, Panigrahy D, Kotelianski V, Langer R, Anderson DG.

Nat Nanotechnol. 2014 Aug;9(8):648-655. doi: 10.1038/nnano.2014.84. Epub 2014 May 11.

15.

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Dong Y, Love KT, Dorkin JR, Sirirungruang S, Zhang Y, Chen D, Bogorad RL, Yin H, Chen Y, Vegas AJ, Alabi CA, Sahay G, Olejnik KT, Wang W, Schroeder A, Lytton-Jean AK, Siegwart DJ, Akinc A, Barnes C, Barros SA, Carioto M, Fitzgerald K, Hettinger J, Kumar V, Novobrantseva TI, Qin J, Querbes W, Koteliansky V, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):3955-60. doi: 10.1073/pnas.1322937111. Epub 2014 Feb 10. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5753.

16.

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.

Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, Manoharan M, Akinc A, Maier MA, Cullis P, Madden TD, Hope MJ.

Mol Ther Nucleic Acids. 2013 Dec 17;2:e139. doi: 10.1038/mtna.2013.66.

17.

Exploiting endocytosis for nanomedicines.

Akinc A, Battaglia G.

Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a016980. doi: 10.1101/cshperspect.a016980. Review.

18.

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, Tam YK, Ansell SM, Kumar V, Qin J, Zhang X, Wang Q, Panesar S, Hutabarat R, Carioto M, Hettinger J, Kandasamy P, Butler D, Rajeev KG, Pang B, Charisse K, Fitzgerald K, Mui BL, Du X, Cullis P, Madden TD, Hope MJ, Manoharan M, Akinc A.

Mol Ther. 2013 Aug;21(8):1570-8. doi: 10.1038/mt.2013.124. Epub 2013 Jun 25.

19.

Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape.

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stöter M, Epstein-Barash H, Zhang L, Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M, Zerial M.

Nat Biotechnol. 2013 Jul;31(7):638-46. doi: 10.1038/nbt.2612. Epub 2013 Jun 23.

PMID:
23792630
20.

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.

Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V.

Mol Ther Nucleic Acids. 2012 Jan 24;1:e4. doi: 10.1038/mtna.2011.3.

21.

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.

Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ.

Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. doi: 10.1002/anie.201203263. Epub 2012 Jul 10.

22.

Treatment of erythropoietin deficiency in mice with systemically administered siRNA.

Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG Jr.

Blood. 2012 Aug 30;120(9):1916-22. doi: 10.1182/blood-2012-04-423715. Epub 2012 May 18.

23.

Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.

Foster DJ, Barros S, Duncan R, Shaikh S, Cantley W, Dell A, Bulgakova E, O'Shea J, Taneja N, Kuchimanchi S, Sherrill CB, Akinc A, Hinkle G, Seila White AC, Pang B, Charisse K, Meyers R, Manoharan M, Elbashir SM.

RNA. 2012 Mar;18(3):557-68. doi: 10.1261/rna.031120.111. Epub 2012 Jan 31.

24.

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR.

Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.

25.

Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.

Manoharan M, Akinc A, Pandey RK, Qin J, Hadwiger P, John M, Mills K, Charisse K, Maier MA, Nechev L, Greene EM, Pallan PS, Rozners E, Rajeev KG, Egli M.

Angew Chem Int Ed Engl. 2011 Mar 1;50(10):2284-8. doi: 10.1002/anie.201006519. Epub 2011 Jan 31. No abstract available.

26.

CSF transthyretin neuroprotection in a mouse model of brain ischemia.

Santos SD, Lambertsen KL, Clausen BH, Akinc A, Alvarez R, Finsen B, Saraiva MJ.

J Neurochem. 2010 Dec;115(6):1434-44. doi: 10.1111/j.1471-4159.2010.07047.x. Epub 2010 Nov 11.

27.

In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR).

Landesman Y, Svrzikapa N, Cognetta A 3rd, Zhang X, Bettencourt BR, Kuchimanchi S, Dufault K, Shaikh S, Gioia M, Akinc A, Hutabarat R, Meyers R.

Silence. 2010 Aug 23;1(1):16. doi: 10.1186/1758-907X-1-16.

28.

Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.

Mahon KP, Love KT, Whitehead KA, Qin J, Akinc A, Leshchiner E, Leshchiner I, Langer R, Anderson DG.

Bioconjug Chem. 2010 Aug 18;21(8):1448-54. doi: 10.1021/bc100041r.

29.

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR, Butler JS, Qin L, Racie T, Sprague A, Fava E, Zeigerer A, Hope MJ, Zerial M, Sah DW, Fitzgerald K, Tracy MA, Manoharan M, Koteliansky V, Fougerolles Ad, Maier MA.

Mol Ther. 2010 Jul;18(7):1357-64. doi: 10.1038/mt.2010.85. Epub 2010 May 11.

30.

Rational design of cationic lipids for siRNA delivery.

Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ.

Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.

PMID:
20081866
31.

Lipid-like materials for low-dose, in vivo gene silencing.

Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, Frank-Kamenetsky M, Yip KN, Alvarez R, Sah DW, de Fougerolles A, Fitzgerald K, Koteliansky V, Akinc A, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9. doi: 10.1073/pnas.0910603106. Epub 2010 Jan 11. Erratum in: Proc Natl Acad Sci U S A. 2010 May 25;107(21):9915.

32.

Development of lipidoid-siRNA formulations for systemic delivery to the liver.

Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Röhl I, Leshchiner ES, Langer R, Anderson DG.

Mol Ther. 2009 May;17(5):872-9. doi: 10.1038/mt.2009.36. Epub 2009 Mar 3.

33.

Assessing siRNA pharmacodynamics in a luciferase-expressing mouse.

Svensson RU, Shey MR, Ballas ZK, Dorkin JR, Goldberg M, Akinc A, Langer R, Anderson DG, Bumcrot D, Henry MD.

Mol Ther. 2008 Dec;16(12):1995-2001. doi: 10.1038/mt.2008.187. Epub 2008 Sep 9.

34.

Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection.

Rodrigues CD, Hannus M, Prudêncio M, Martin C, Gonçalves LA, Portugal S, Epiphanio S, Akinc A, Hadwiger P, Jahn-Hofmann K, Röhl I, van Gemert GJ, Franetich JF, Luty AJ, Sauerwein R, Mazier D, Koteliansky V, Vornlocher HP, Echeverri CJ, Mota MM.

Cell Host Microbe. 2008 Sep 11;4(3):271-82. doi: 10.1016/j.chom.2008.07.012.

35.

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.

Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Röhl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20. doi: 10.1073/pnas.0805434105. Epub 2008 Aug 11.

36.

Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection.

Epiphanio S, Mikolajczak SA, Gonçalves LA, Pamplona A, Portugal S, Albuquerque S, Goldberg M, Rebelo S, Anderson DG, Akinc A, Vornlocher HP, Kappe SH, Soares MP, Mota MM.

Cell Host Microbe. 2008 May 15;3(5):331-8. doi: 10.1016/j.chom.2008.04.003.

37.

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG.

Nat Biotechnol. 2008 May;26(5):561-9. doi: 10.1038/nbt1402. Epub 2008 Apr 27.

38.

Delivering silence: advancements in developing siRNA therapeutics.

Novobrantseva TI, Akinc A, Borodovsky A, de Fougerolles A.

Curr Opin Drug Discov Devel. 2008 Mar;11(2):217-24. Review.

PMID:
18283609
39.

Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway.

John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D.

Nature. 2007 Oct 11;449(7163):745-7. Epub 2007 Sep 26.

40.

Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide.

Xia J, Noronha A, Toudjarska I, Li F, Akinc A, Braich R, Frank-Kamenetsky M, Rajeev KG, Egli M, Manoharan M.

ACS Chem Biol. 2006 Apr 25;1(3):176-83.

PMID:
17163665
41.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
42.

Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters).

Anderson DG, Akinc A, Hossain N, Langer R.

Mol Ther. 2005 Mar;11(3):426-34.

43.

Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis.

Akinc A, Thomas M, Klibanov AM, Langer R.

J Gene Med. 2005 May;7(5):657-63.

PMID:
15543529
44.

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP.

Nature. 2004 Nov 11;432(7014):173-8.

45.

A polymer library approach to suicide gene therapy for cancer.

Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R, Langer R, Sawicki JA.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33. Epub 2004 Nov 1.

46.

Severe osteoporosis after early orchidectomy: is it inevitable?

Ozçakar L, Erol O, Doğan S, Sener D, Akinc A.

BJU Int. 2003 Oct;92(6):652-3. No abstract available.

47.

Synthesis of poly(beta-amino ester)s optimized for highly effective gene delivery.

Akinc A, Anderson DG, Lynn DM, Langer R.

Bioconjug Chem. 2003 Sep-Oct;14(5):979-88.

PMID:
13129402
48.

Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery.

Akinc A, Lynn DM, Anderson DG, Langer R.

J Am Chem Soc. 2003 May 7;125(18):5316-23.

PMID:
12720443
49.

Supplemental Content

Support Center